FDA focuses on poisonous side effects with Onyx drug

<p>WASHINGTON (AP) — The poisonous side effects of an initial <span>cancer drug</span> from <span>Onyx Pharmaceuticals</span> might transcend a advantages for patients with a form of blood <span>cancer</span>, <span>federal health</span> regulators pronounced Monday.</p>
<p>The <span>Food and Drug Administration</span> warned that patients in a association investigate of a drug had a high rate of heart and lung side effects, some that were fatal. The FDA posted a examination of carfilzomib online forward of a assembly Wednesday, where a row of cancer experts will suggest either a drug should be approved.</p>
<p>Shares of <span>Onyx Pharmaceuticals Inc.</span>, formed in San Francisco, rose 2 cents to $46 in morning trade after rising as high as $46.99 progressing in a session. They are nearby their 52-week high of $47.80 in late April.</p>
<p>Onyx has asked a FDA to approve...